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Abstract 
Primitive neuroectodermal tumor (PNET) of
the kidney is a rare and highly malignant neo-
plasm. The median age for renal PNET is 27
years but it can be seen also in a wide age
range between 3 and 78 years. We performed a
Medline search for the term renal PNET and
identified 79 cases up till December of 2010.
We report here a new case of renal PNET and a
literature review for published data for evalua-
tion of clinicopathological prognostic factors,
with an emphasis on prognosis in two groups
of adults and children-adolescents: 18 years of
age or under and over 18 years.
Introduction
Primitive neuroectodermal tumor (PNET) of
the kidney is a rare and highly malignant neo-
plasm. The median age for renal PNET is 27
years but it can be seen in a wide age range
between 3 and 78 years.1It affects young adults
and only a few pediatric and adolescent cases
(18 years or under) have been reported. Renal
PNET  needs  to  be  differentiated  from  other
small round cell tumors of the kidney, because
of the different treatment modalities required.
Diagnosis of this neoplasm is currently based
on a combination of light microscopy, immuno-
histochemistry  (IHC)  and  reverse  transcrip-
tase  polymerase  chain  reaction  (RT-PCR),2-4
and a multimodality treatment approach, such
as surgical resection and chemotherapy with
or without radiotherapy, is recommended for
these patients. There is a high recurrence rate
and  a  tendency  to  metastasize  to  regional
lymph nodes, lungs, liver, bone and bone mar-
row at an early disease stage. However, prog-
nosis seems to be better in younger patients.5,6
We  performed  a  MEDLINE  search  for  the
term renal PNET and identified 79 cases up till
December of 2010. Patients with insufficient
data, such as lack of clinicopathological data
and IHC, were excluded. We report a new case
of renal PNET and a literature review for pub-
lished data for evaluation of clinicopathologi-
cal  prognostic  factors,  with  an  emphasis  on
prognosis in two groups of adults and children-
adolescents: 18 years of age or under and over
18  years.  The  data  obtained  for  renal  PNET
were analyzed using the Kaplan-Meier method
with SPSS version 17.5. P <0.05 was consid-
ered significant.
Case Report
A 3-year old boy was admitted to our hospi-
tal with abdominal pain and a large palpable
mass  on  the  left  side  of  the  abdomen.
Sonography showed a tumor of the left kidney.
Computer  tomography  revealed  a  large  left
inhomogeneous  renal  mass  of  12  cm  with
areas of necrosis and bleeding. There was no
obvious lymphadenopathy and no intraabdom-
inal  metastasis.  Laboratory  evaluation  was
normal in CBC: UA catecholamine metabolite
only LDH level was 890 IU/L.
A left radical nephrectomy with lymph node
dissection  was  performed.  Gross  pathology
examination confirmed kidney dimensions of
14ﾥ12ﾥ8 cm. The tumor involved a large por-
tion of the pole of the kidney. The tumor was
4.5  cm  in  diameter  at  its  widest  point  with
infiltration to the renal pelvis. The renal vein,
urethra  and  lymph  nodes  were  negative  for
malignancy.  Histolological  examination
revealed small round undifferentiated tumoral
cells with scant cytoplasm, oval to round with
hyperchromatic  nuclei.  The  tumor  had  mas-
sive areas of necrosis without rosette or tubule
formation.  The  renal  capsule  was  infiltrated
with  tumor.  The  morphological  report  con-
firmed a small round cell tumor.
Immunohistochemistry revealed that tumor
cells were strongly positive for Mic2 (CD99) as
well as vimentin and Neuron-Specific Enolase
(NSE).  The  tumor  cells  were  negative  for
synaptopohsin and Wilm’s tumor (WT1), cytok-
eratin,  neuroblastoma,  neurofilament,  leuko-
cyte  common  antigen,  myogenin,  S-100  and
desmin. Chromosomal evaluation showed the
patient was positive for EWS-FLI1 transloca-
tion in PCR.
Metastatic  workup  showed  there  was  no
metastasis on bone scintigraphy and thorax CT
scan.  Bilateral  iliac  bone  marrow  biopsies
showed no evidence of neoplastic involvement.
The  patient  received  chemotherapy  with
vicristin, adriamycin, cyclophosphamide alter-
nating with etoposide, ifosfamide and mesna
for 48 weeks. No serious adverse effects were
reported  during  chemotherapy.  The  patient
received radiation therapy to the tumor bed for
minimal residual disease due to extracapsular
invasion for 40 GY in 22 fractions. 
There  was  no  evidence  of  disease  at  56
months  from  diagnosis  and  no  late  adverse
effects have been noted. This is the youngest
patient to be reported with renal PNET.
Results
We found 80 cases of renal PNET (40 males
and  39  females)  reported  in  literature.  (A
detailed  list  of  all  cases  is  available  on
request.) Median age at renal PNET diagnosis
reported  in  a  published  series  is  27  years
(mean=29.43±16.31, range 3-78 years). In the
18  years  and  under  age  group,  59.1%  are
between 13-18 years and 44.8% of patients over
18 years are between 20-29 years. There are 7
males and 14 females aged 18 years and under
versus 33 males and 25 females aged over 18
years. 
Flank pain is the most frequent of symptoms
and signs (67.5%) in renal PNET followed by
hematuria  (33.8%)  and  mass  (33.8%),  IVC
thrombosis  (25%)  and  weight  loss  (16%).
There is no relation between clinical manifes-
tation and survival or between clinical signs
and age.
Follow-up data were available for 68 patients
with renal PNET with a median follow up of 12
months (interquartile range 5-19.5); 36 (45%)
died of their disease and 66.7% of patients in
the younger group had no evidence of disease
versus 38.3% in the older group (P=0.03).
One-year survival was 50.2 vs. 34.2% and 2-
year  survival  was  30.1%  versus  18.4%  in
patients aged 18 years and under and those
over  18  years,  respectively  (95%  CI;  11-21).
However, there was no statistically significant
difference  in  overall  survival  (log  rank  test
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P=0.08), with median survival 24.1 months for
patients aged 18 under and 14.6 months for
those  aged  over  18  years,  respectively.  Five-
year  survival  with  disease  free  status  was
found in 2 cases in the 18 years and under age
group,  but  none  in  the  over  18  years  group
(Figure 1). There were significant differences
in death rate between the younger and older
groups:  37.5%  versus  70%,  respectively
(P=0.024) 
Forty-four  (55%)  of  these  patients  had
metastases at presentation: 12 to liver, 26 to
lung and 19 to lymph node. Liver metastasis is
more  frequent  in  those  aged  18  years  and
under, and lung, lymph node and bone metas-
tases in patients aged over 18 years. There was
more  metastatic  disease  in  the  older  group
than the younger group: 73.3% versus 50% (CI:
60, 87% versus CI: 27, 73%, P=0.059) and the
mean  age  of  patients  with  metastasis  is
29.3±14.9  years  versus  22.8±14.6  years  in
patients  without  metastases  (P<0.05).
Younger patients with metastatic disease have
better survival than older patients (log rank
P=0.3) (Figure 2). In patients aged 18 years
and under, 1-year survival in local and metasta-
tic disease was 77.7% and 50.2%, respectively
(log rank P=0.2) whereas in patients aged over
18 years these rates were 64.7% and 34.2%,
respectively,  although  this  difference  was
without  statistical  significance  (log  rank
P=0.18).
Survival rate in lung metastasis was signifi-
cantly lower than local disease: median sur-
vival  (CI  95%):  14  (range  3-25)  versus  60
(range 9-111) months; log rank test P=0.02.
Lymph  node  involvement  was  22.7%  versus
30.4% in patients aged 18 years and under and
those over 18 years, respectively. Differences
in survival between lymph node positive and
negative was not significant in cases aged 18
years  and  under  (mean  survival  23  vs  62
months),  but  there  was  a  significant  differ-
ence in cases aged over 18 years (mean sur-
vival 5 vs 31 months; log rank test P=0.000)
(Figure 3).
Immunohistochemical analysis found CD-99
was  positive  in  the  majority  of  patients  fol-
lowed by NSE, vimentin, S-100 and synaptopy-
sin.  Sixty-seven  patients  were  evaluated  for
EWS-FLI1 translocation in PCR. There was no
relation between immunohistochemical mark-
ers and survival function (Table 1).
Discussion
The peripheral neuroectodermal tumor, first
recognized by Arthur Purdy Stout in 1918, is a
member  of  the  family  of  small  round-cell
tumors.7 PNET is a primitive, poorly differenti-
ated round cell neoplasm of neuroectodermal
origin  that  presents  outside  the  central  and
sympathetic nervous system. PNET is a malig-
nant disease of young adult and the first report
of renal PNET was by Seemayer in 1975.8 But
renal PNET is a rare disease with a wide age
range at presentation between early childhood
to late adulthood.6
Diagnosis of renal PNET must be considered
in young patients with renal neoplasm, partic-
ularly those with advanced disease at presen-
tation.9 The  diagnosis  of  PNET  is  based  on
pathological  findings.  Application  of  the  full
range  of  diagnostic  methods  is  necessary
because the use of a single diagnostic method
is not enough to exclude the large number of
differential  diagnoses,  such  as  desmoplastic
tumor, Wilm’s tumor, neuroblastoma, small cell
carcinoma,  malignant  lymphoma,  renal  cell
carcinoma and other tumors depending on age
at presentation. However, diagnosis must be
made rapidly so that the patient can receive
effective therapy as soon as possible.
Several diagnostic approaches can be used
when  there  is  suspicion  of  PNET.  The  first
approach is light microscopic examination of
tumor  tissue  including  immunohistochem-
istry. These tumors consist of primitive looking
round cells with high nucleous to cytoplasmic
ratio.  The  immunohistochemical  features  of
PNET are often positive for CD99 (mic2), NSE
expression was detected in 95%, and vimentin,
S-100,  and  synaptophysin  and  chromogranin
were  expressed  in  the  majority  of  patients
(60%). However, expression of CD99 is by no
means  specific  for  PNET  among  round  cell
tumors.10 A third approach is the presence of
EWS-FLI  chromosomal  translocation  that  is
positive in 88-95% of PNET cases.11-12 But in
Case Report
Figure 3. Survival function according to
lymph node involvement in patients ≤18
years old and >18 years old.
Table 1. Survival function by immunohisthochimestrty features (Neuron-Specific Enolase
negative was not mentioned in case reports). 
Mean survival 95% confidence
(months) interval
Neuron Specific Enolase + 30 (20, 40)
Vimentin – 13 (4, 22)
+ 50 (30, 70)
S-100 + 23 (15, 31)
– 22 (9, 35)
Synaptophysin + 39 (13, 64)
– 32 (13, 52)
Figure 1. Overall survival function in age
groups.
Figure  2.  Survival  function  in  metastatic
patients by age groups.[Rare Tumors 2012; 4:e15] [page 51]
renal  PNET,  the  positive  frequency  of  these
markers is different and NSE is less frequent.
Some  studies  showed  that  the  presence  of
some  IHC  markers,  such  as  chromogranin,
may play a negative role in terms of survival.9
However,  in  this  study,  no  relation  between
IHC markers and patient outcome was found.
When diagnosis is not clear on the basis of
pathology and immunohistochemistry, molecu-
lar markers (EWS-FLI chromosomal transloca-
tion) have been proved to be exceedingly use-
ful, especially in cases of unusual morphology
and small biopsy in renal mass.13 Some studies
(but not all) have suggested that the type of
fusion may have prognostic significance, with
some studies showing a positive association
between EWS-FLI1 fusions and longer survival
in ESF tumors.14,15 However, we found no dif-
ference  between  EWS-FLI1  and  survival  in
patients with renal PNET.
The number of renal PNET case reports has
grown in the past few years due to better dif-
ferential diagnosis of renal tumors resulting
from advances in immunohistochemistry and
PCR methods. We, therefore, believe that the
number of cases of renal PNET is underesti-
mated; a review of pathological specimens in
National Wilm’s Tumor Study by IHC and RT-
PCR  found  more  renal  PNET  than  Wilm’s
tumor under light microscopy.16,17
The survival rate of patients with organ-con-
fined  PNET  is  unknown,  but  hopefully  an
aggressive  multidisciplinary  treatment
approach  will  provide  a  cure.18 Treatment
should consist of a combination of surgery and
chemotherapy. Complete resection of the kid-
ney with node sampling should be performed if
at  all  feasible.  There  is  a  definite  role  for
chemotherapy  in  this  disease,  and  best
responses  are  seen  with  combinations  con-
taining anthracyclines and high doses of alky-
lating agents alternating with ifosfamide and
etoposide. Radiation therapy is recommended
for  patients  with  residual  tumor  or  positive
margins after surgery. The role of radiotherapy
in the absence of residual disease or extracap-
sular extention is not known.19,20
Renal mass, and pain and hematuria are
the most frequent presenting symptoms, and
weight  loss  is  more  frequent  in  younger
patients.  Ellinger  et  al.9 showed  that  the
patients with renal mass had a low survival
rate but we found no relation between symp-
toms and signs with survival. 
Ewing Sarcoma Families (ESF) are aggres-
sive  neoplasms;  about  25%  of  patients  have
clinically  apparent  metastatic  disease  at  the
time  of  diagnosis.  Nevertheless,  despite
aggressive treatment, 30-40% of patients with
localized  disease,  and  80%  of  patients  with
metastatic disease, die due to disease progres-
sion.21 Patients with localized ESF have a 5-
year disease-free survival rate of approximate-
ly  60  to  70%.22 Analyzing  the  data  obtained
from case reports, 75% of patients with local-
ized renal PNET were free of disease after a
period  of  4-90  months.  Overall,  47.1%  of
patients, 66.7% of cases aged 18 years or under
and 38.3% aged over 18 years, had no evidence
of disease during follow up. Despite aggressive
treatment,  the  prognosis  of  patients  with
metastatic disease is poor. For metastatic EFF,
the  overall  cure  rate  has  been  20%,  and  in
renal  PNET  among  metastatic  sites  the
patients with lymph node and lung metastases
have poor survival.23,24
Our results seem to show that children and
young adults have less metastatic disease and
have a better outcome even if they have metas-
tases. The effect of age on survival is contra-
dictory in ESF tumors. In some studies, out-
come was better in younger patients in uni-
variate and multivariate analysis18,23,25,26 while
others did not influence survival; cut-off points
were between 12 to 26 years of age. Median
age  at  diagnosis  of  ESF,  according  to  the
National  Cancer  Institute’s  Surveillance
Epidemiology and End Results (SEER) data for
the  period  1973  to  1987,  was  15  years.22,27
Therefore,  approximately  one  half  of  all
patients diagnosed with an ESF tumor will be
over 15 years of age, and it is important to
remember that it is just as frequently found in
young adults as in children. In most studies,
older age has been reported to have an unfa-
vorable prognostic factor.18,28,29 Several charac-
teristics of adult Ewing’s sarcoma, such as a
different pattern of primary tumor sites (e.g.
axial location), a larger tumor size, and a lower
intensity of chemotherapy dose, may explain
why the prognosis in adults is seemingly less
favorable.  Our  findings  suggest  that  adult
patients  with  renal  PNET,  like  other  ESF
tumors, have poorer outcomes than younger
patients and must treated by aggressive proto-
cols, like pediatric protocols. 
In conclusion, although primitive neuroec-
todermal tumor is extremely rare in the kidney,
the  past  two  decades  have  seen  this  tumor
diagnosed more frequently. This is due to bet-
ter  diagnostic  methods,  such  as  IHC  and
molecular markers, for differential diagnosis
with other renal masses. Renal PNET involves
a wide age range at presentation but the medi-
an  age  at  presentation  is  approximately  15
years  older  than  other  ESF.  Patients  in  the
older age group have more poor prognostic fac-
tors and lower survival than children and ado-
lescents  and  should  be  treated  with  more
aggressive protocols. Renal PNET in younger
patients  could  have  a  better  prognosis  even
with distant and regional metastases. 
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